Expansion of Quotient Sciences' UK drug development and manufacturing facilities

Quotient Sciences’ Nottingham and Reading facilities have announced the completion of their facility expansions, providing further capabilities to support their flagship program Translational Pharmaceutics®.

As a platform, Translational Pharmaceutics integrates programs for drug substance, drug product, and clinical testing activities under a single outsourcing provider, with the goal of accelerating development timelines while reducing costs. The platform, which utilises rapid “make-test” cycles wherein drug products run through the clinical study manufacturing, release, and dosing process in days, was developed with consultation from the MHRA and US FDA. Quotient Sciences’ investments in their expanded laboratory and clinical pharmacology spaces will increase their capacity to conduct programs with Translational Pharmaceutics. 

Quotient Sciences Nottingham facility boasts an MHRA-inspected clinical pharmacology facility spanning 17,000 square feet, with processing labs, a dispensary, and controlled storage. The facility sits alongside their existing facilities specialising in formulation development, manufacturing, and clinical operations. Their Reading site has completed a GBP £1.5 million expansion for its early development and manufacturing facility.  

Mark Egerton, CEO of Quotient Sciences, commented: “Quotient Science’s mission is to help bring new medicines to patients faster by breaking own traditional industry silos... Our Unique Translational Pharmaceutics platform was launched over 15 years ago and has accelerated the development of close to 1,000 molecules for our customers. These expansions are consistent with our overall growth strategy and in direct response to feedback from our customers and the increasing demand for our services.” 

Source: Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics®